Can antisense for p53 increase the chemosensitivity of anticancer drugs for lung cancer?

p53反义可以增加肺癌抗癌药物的化疗敏感性吗？

• 批准号: 10671133
• 负责人: KAWAMURA Masafumi
• 金额: $ 1.92万
• 依托单位: Keio university
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1998
• 资助国家: 日本
• 起止时间: 1998 至 1999
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-10671133/
• 关键词: anticacer drug; chemosensitivity testing; p53; antisense; cancer suppression gene; p53

Chemosensitivity testing of anticancer drugs for lung cancer was measured by use of collagen gel droplet embedded drug sensitivity test (CDDST). Corelation between CDDST and clinical response was as below. True positive ratio was 80%. True negative ratio was 100%. Accuracy was 83.3%. Chemosensitivity testings were successfully carried out in 77.2% of 149 resected tumor specimen, 34.1% of 44 bronchoscopic biopsied specimens, 73.6% of 72 disected or biopsied lymph nodes, and 56.4% of 39 aspirated pleural or pericardial effusion. Chemosensitivities of some anticancer drugs for some lung cancercell lines were increased at 42℃ incubation in CDDST.Apoptosis in lung cancer cell lines could be induced at 42℃ in CDDST, if incubation time was prolonged. During this process, increase of p53 m-RNA could not detected. In lung cancer cell line apoptosis might be initiated by activation of p53 protein itself and p53 m-RNA might not relate directly with the initiation of apoptosis. Actually the increase of chemosensitivity of anticancer drugs for lung cancer cell lines were not observed in CDDST with p53 antisense.

采用胶原凝胶滴包埋药敏试验（CDDST）测定肺癌抗癌药物的化疗敏感性。CDDST与临床反应的相关性如下：真阳性率为80%。真阴性率为100%。准确率为83.3%。149例肿瘤切除标本中有77.2%、44例支气管镜活检标本中有34.1%、72例淋巴结切除或活检标本中有73.6%、39例胸腔或心包积液中有56.4%进行了化疗敏感性检查。在CDDST 42℃孵育下，某些肺癌细胞株对某些抗癌药物的化学敏感性有所提高。CDDST在42℃下可诱导肺癌细胞凋亡，但需延长孵育时间。在此过程中，p53 m-RNA未见增加。肺癌细胞系的凋亡可能通过p53蛋白自身的激活而启动，而p53 m-RNA可能与凋亡的启动没有直接关系。实际上，p53反义CDDST对肺癌细胞系的化疗敏感性并没有增加。

项目成果

川村雅文: "抗癌剤感受性試験に基づいた肺癌の化学療法"肺癌の臨床. 1(3). 353-360 (1998)

Masafumi Kawamura：“基于抗癌药物敏感性测试的肺癌化疗”《肺癌临床》1(3)。

川村 雅文: "抗癌剤感受性試験に基づいた肺癌の化学療法" 肺癌の臨床. 1巻3号. 353-360 (1998)

Masafumi Kawamura：“基于抗癌药物敏感性测试的肺癌化疗”《肺癌临床》第1卷第3期353-360（1998）

Masafumi Kawamura, Masatoshi Gika, Koichi Kobayashi: "Chemosensitivity testing for lung cancer"Jpn.J.Lung Cancer Clin.. 1(3). 353-360 (1998)

Masafumi Kawamura、Masatoshi Gika、Koichi Kobayashi：“肺癌的化学敏感性测试”Jpn.J.Lung Cancer Clin.. 1(3)。

Masafumi Kawamura, Masayoshi Inoue, Tomohiro Abiko, et al: "Neoadjuvant chemotherapy for cN2 non-small cell lung cancer based on chemosensitivity testing"Controversy on lung cancer treatment-Record of 14th Workshop of Jpn.Lung Cancer Society. 107-113 (199

Masafumi Kawamura、Masayoshi Inoue、Tomohiro Abiko等：“基于化疗敏感性测试的cN2非小细胞肺癌新辅助化疗”肺癌治疗争议——日本肺癌学会第14届研讨会记录。

川村雅文: "C-N2非小細胞肺癌に対する手術を中心に据えた治療戦略-抗癌剤感受性試験に基づいた術前化学療法の可能性-"第14回肺癌学会ワークショップ記録集. 107-113 (1999)

Masafumi Kawamura：“以手术为中心的C-N2非小细胞肺癌的治疗策略-基于抗癌药物敏感性测试的术前化疗的可能性-”第14届肺癌学会研讨会记录（1999）。